Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 78

1.

NPM1-mutated AML: targeting by disassembling.

Falini B, Martelli MP.

Blood. 2011 Sep 15;118(11):2936-8. doi: 10.1182/blood-2011-07-366146. No abstract available.

PMID:
21921055
[PubMed - indexed for MEDLINE]
Free Article
2.

Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1.

Balusu R, Fiskus W, Rao R, Chong DG, Nalluri S, Mudunuru U, Ma H, Chen L, Venkannagari S, Ha K, Abhyankar S, Williams C, McGuirk J, Khoury HJ, Ustun C, Bhalla KN.

Blood. 2011 Sep 15;118(11):3096-106. doi: 10.1182/blood-2010-09-309674. Epub 2011 Jun 30.

PMID:
21719597
[PubMed - indexed for MEDLINE]
Free Article
3.

Suramin: an anticancer drug with unique biological effects.

Larsen AK.

Cancer Chemother Pharmacol. 1993;32(2):96-8. Review. No abstract available.

PMID:
8387401
[PubMed - indexed for MEDLINE]
4.

Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1).

Falini B, Macijewski K, Weiss T, Bacher U, Schnittger S, Kern W, Kohlmann A, Klein HU, Vignetti M, Piciocchi A, Fazi P, Martelli MP, Vitale A, Pileri S, Miesner M, Santucci A, Haferlach C, Mandelli F, Haferlach T.

Blood. 2010 May 6;115(18):3776-86. doi: 10.1182/blood-2009-08-240457. Epub 2010 Mar 4. Erratum in: Blood. 2010 Aug 12;116(6):1017.

PMID:
20203266
[PubMed - indexed for MEDLINE]
Free Article
5.

Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity?

Falini B, Martelli MP, Bolli N, Sportoletti P, Liso A, Tiacci E, Haferlach T.

Blood. 2011 Jan 27;117(4):1109-20. doi: 10.1182/blood-2010-08-299990. Epub 2010 Oct 28. Review.

PMID:
21030560
[PubMed - indexed for MEDLINE]
Free Article
6.

CD34+ cells from AML with mutated NPM1 harbor cytoplasmic mutated nucleophosmin and generate leukemia in immunocompromised mice.

Martelli MP, Pettirossi V, Thiede C, Bonifacio E, Mezzasoma F, Cecchini D, Pacini R, Tabarrini A, Ciurnelli R, Gionfriddo I, Manes N, Rossi R, Giunchi L, Oelschlägel U, Brunetti L, Gemei M, Delia M, Specchia G, Liso A, Di Ianni M, Di Raimondo F, Falzetti F, Del Vecchio L, Martelli MF, Falini B.

Blood. 2010 Nov 11;116(19):3907-22. doi: 10.1182/blood-2009-08-238899. Epub 2010 Jul 15.

PMID:
20634376
[PubMed - indexed for MEDLINE]
Free Article
7.

Acute myeloid leukemia with mutated nucleophosmin (NPM1): molecular, pathological, and clinical features.

Falini B.

Cancer Treat Res. 2010;145:149-68. doi: 10.1007/978-0-387-69259-3_9.

PMID:
20306250
[PubMed - indexed for MEDLINE]
8.

AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features.

Haferlach C, Mecucci C, Schnittger S, Kohlmann A, Mancini M, Cuneo A, Testoni N, Rege-Cambrin G, Santucci A, Vignetti M, Fazi P, Martelli MP, Haferlach T, Falini B.

Blood. 2009 Oct 1;114(14):3024-32. doi: 10.1182/blood-2009-01-197871. Epub 2009 May 8.

PMID:
19429869
[PubMed - indexed for MEDLINE]
Free Article
9.

Localization and altered expression of nucleophosmin in the nuclear matrix during the differentiation of human hepatocarcinoma SMMC-7721 cells induced by HMBA.

Li QF, Tang J, Liu QR, Shi SL, Chen XF.

Cancer Invest. 2010 Dec;28(10):1004-12. doi: 10.3109/07357900902918452. Epub 2010 Aug 6.

PMID:
20690796
[PubMed - indexed for MEDLINE]
10.

Acute myeloid leukemia with mutated NPM1: diagnosis, prognosis and therapeutic perspectives.

Falini B, Sportoletti P, Martelli MP.

Curr Opin Oncol. 2009 Nov;21(6):573-81. doi: 10.1097/CCO.0b013e3283313dfa. Review.

PMID:
19770764
[PubMed - indexed for MEDLINE]
11.

NPM1 but not FLT3-ITD mutations predict early blast cell clearance and CR rate in patients with normal karyotype AML (NK-AML) or high-risk myelodysplastic syndrome (MDS).

Schneider F, Hoster E, Unterhalt M, Schneider S, Dufour A, Benthaus T, Mellert G, Zellmeier E, Bohlander SK, Feuring-Buske M, Buske C, Braess J, Fritsch S, Heinecke A, Sauerland MC, Berdel WE, Buechner T, Woermann BJ, Hiddemann W, Spiekermann K.

Blood. 2009 May 21;113(21):5250-3. doi: 10.1182/blood-2008-09-172668. Epub 2009 Mar 11.

PMID:
19279329
[PubMed - indexed for MEDLINE]
Free Article
12.

Targeting tumors through the HIF system.

Ratcliffe PJ, Pugh CW, Maxwell PH.

Nat Med. 2000 Dec;6(12):1315-6. No abstract available.

PMID:
11100107
[PubMed - indexed for MEDLINE]
13.

Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias.

Falini B, Nicoletti I, Bolli N, Martelli MP, Liso A, Gorello P, Mandelli F, Mecucci C, Martelli MF.

Haematologica. 2007 Apr;92(4):519-32. Review.

PMID:
17488663
[PubMed - indexed for MEDLINE]
Free Article
14.

Role of Npm1 in proliferation, apoptosis and differentiation of neural stem cells.

Qing Y, Yingmao G, Lujun B, Shaoling L.

J Neurol Sci. 2008 Mar 15;266(1-2):131-7. Epub 2007 Oct 18.

PMID:
17949752
[PubMed - indexed for MEDLINE]
15.

IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.

Paschka P, Schlenk RF, Gaidzik VI, Habdank M, Krönke J, Bullinger L, Späth D, Kayser S, Zucknick M, Götze K, Horst HA, Germing U, Döhner H, Döhner K.

J Clin Oncol. 2010 Aug 1;28(22):3636-43. doi: 10.1200/JCO.2010.28.3762. Epub 2010 Jun 21.

PMID:
20567020
[PubMed - indexed for MEDLINE]
Free Article
16.

Minimal residual disease detection in acute myeloid leukemia by mutant nucleophosmin (NPM1): comparison with WT1 gene expression.

Barragan E, Pajuelo JC, Ballester S, Fuster O, Cervera J, Moscardo F, Senent L, Such E, Sanz MA, Bolufer P.

Clin Chim Acta. 2008 Sep;395(1-2):120-3. doi: 10.1016/j.cca.2008.05.021. Epub 2008 Jun 8.

PMID:
18590714
[PubMed - indexed for MEDLINE]
17.

Alteration of nuclear matrix-intermediate filament system and differential expression of nuclear matrix proteins during human hepatocarcinoma cell differentiation.

Tang J, Niu JW, Xu DH, Li ZX, Li QF, Chen JA.

World J Gastroenterol. 2007 May 28;13(20):2791-7.

PMID:
17569113
[PubMed - indexed for MEDLINE]
Free Article
18.

New anticancer strategies targeting HIF-1.

Yeo EJ, Chun YS, Park JW.

Biochem Pharmacol. 2004 Sep 15;68(6):1061-9. Review.

PMID:
15313402
[PubMed - indexed for MEDLINE]
19.

Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML.

Schnittger S, Kern W, Tschulik C, Weiss T, Dicker F, Falini B, Haferlach C, Haferlach T.

Blood. 2009 Sep 10;114(11):2220-31. doi: 10.1182/blood-2009-03-213389. Epub 2009 Jul 8.

PMID:
19587375
[PubMed - indexed for MEDLINE]
Free Article
20.

Immunohistochemistry and molecular analyses in myeloid sarcoma of the breast in a patient with relapse of NPM1-mutated and FLT3-mutated AML after allogeneic stem cell transplantation.

Choschzick M, Bacher U, Ayuk F, Lebeau A.

J Clin Pathol. 2010 Jun;63(6):558-61. doi: 10.1136/jcp.2009.071357. Epub 2010 Apr 1.

PMID:
20360144
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk